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Rationale: Acute-on-chronic liver failure (ACLF) is a life-threat-
ening acute deterioration of a chronic liver disease with severe
jaundice and hepatic encephalopathy. There are no cost-of-illness
studies of the treatment of ACLF available. OBJECTIVES: To
determine the average cost of the treatment of ACLF and testing
of important clinical variables for their predictive value for the
treatment costs. Methodology: Based on the sample of all ACLF-
patients treated in a large German university hospital from 1999
to 2001 detailed cost of the initial hospital stay and a three year
follow-up period were determined. Data on resource use were
collected from hospitals patient ﬁles and internal statistics as well
as by standardized interviews and questionnaires to patients and
their treating GPs. Costs were calculated from a German health
care system perspective and standardized to EUR of 2002. Addi-
tionally to age, sex, aetiology and severity of liver failure another
15 relevant clinical variables were tested in single and multiple
regression analyses. RESULTS: A total of 69 patients with ACLF
could be identiﬁed. Mean costs per patient were €21,058;
€11,259 for the initial hospital stay and €9799 for the following
3 years. Biggest inﬂuence had treatment with artiﬁcial liver
support systems. Other signiﬁcant variables in the model were
renal dialysis and aetiology of the disease. All other variables
including sex, age, severity of ACLF and several laboratory para-
meter did not have a relevant inﬂuence on the costs. CONCLU-
SION: A straight and relatively simple method to identify the
main cost drivers for ACLF-treatment is presented. The results
are absolutely plausible from a clinical point of view and stable
to variation of the model structure. The results underline the
necessity to differentiate the reimbursement systems for hepa-
torenal syndrome or additional renal failure, artiﬁcial liver
support and the aetiology of ACLF.
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OBJECTIVES: Gastroesophageal reﬂux disease (GERD) is a
chronic, potentially debilitating condition characterized by 
frequent and persistent heartburn and acid regurgitation. The
objective of this study was to evaluate the effects of GERD on
work productivity, deﬁned as productivity loss due to absen-
teeism and reduced effectiveness while working (presenteeism).
METHODS: Studies quantifying health-related work productiv-
ity loss in individuals with GERD were identiﬁed using system-
atic literature searches. Work productivity loss due to
absenteeism was expressed as number of hours lost, and as the
percentage of the total employed time. Presenteeism was
expressed as number of hours lost, and as the percentage reduced
effectiveness while at work. Overall productivity losses (absen-
teeism plus presenteeism) were valued in US dollars using the
human capital method. RESULTS: Six publications covering ﬁve
studies conducted in the USA, Canada and Sweden were eligible
for inclusion. Reported work productivity losses among individ-
uals with GERD ranged from 6% to 40%, and were primarily
due to presenteeism (6%–40%) rather than absenteeism
(<1%–6%). Work productivity impairment correlated with
symptom severity, and was greatest in patients experiencing sleep
disturbance due to GERD symptoms and lowest in GERD
patients taking prescription medication. Acid-suppressive
therapy improved productivity at work, especially in individuals
with GERD-associated sleep disturbances. The mean overall pro-
ductivity losses per employee with GERD were estimated at
$51–$396 per week, assuming a 40-hour working week and
average US wages. CONCLUSION: GERD has a substantial eco-
nomic impact, primarily by impairing employee productivity
while at work. The burden of lost productivity may be reduced
by acid-suppressive therapy, especially in employees with night-
time symptoms of GERD.
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OBJECTIVES: To compare the accuracy of two absenteeism
measures (days missed and hours missed) for inclusion in 
economic evaluations of IBS. METHODS: 135 IBS patients
recruited from ﬁve US gastroenterology practices completed the
Work Productivity and Activity Impairment questionnaire for
IBS (WPAI : IBS), which assesses absenteeism with hours missed,
and also completed questions about days and partial days
missed. Days and partial days were considered to be the equiv-
alent of 8 hours and 4 hours, respectively. RESULTS: 125
patients were employed, had complete data, and were included
in the analysis. A total of 6.4% of patients reported missing days
from work due to IBS in the prior 7 days, with an overall absen-
teeism rate of 1.8%; 28.0% of patients reported missing hours,
with an overall absenteeism rate of 4.3%. Among those report-
ing hours missed, 42.9% missed less than 3 hours, 34.3% missed
3 to 5 hours, and 22.9% missed 8 to 30 hours. When days missed
was used to measure absenteeism, 77.2% of patients missing
hours and 60.7% of time missed due to IBS were not counted;
when hours missed was reported, all patients reporting days
missed were counted. Combining partial days missed with days
missed increased the correspondence between those reporting
days and hours missed, but considerably overstated absenteeism
because partial-day absences were often less than 4 hours. Pre-
vious validation of the WPAI : IBS hours missed measure of
absenteeism relative to measures of disease severity, verbatim
responses and retrospective diaries, corroborates the inaccuracy
of the days missed measure. CONCLUSIONS: Hours missed
from work, not days missed, is a more accurate measure for cap-
turing the partial-day absences characteristic of IBS patients.
Other chronic disorders like IBS may exhibit a similar pattern of
widespread absences of short duration, and that absenteeism
may go undetected when days missed is the measure of 
absenteeism.
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OBJECTIVES: In Brazil it is estimated that there are more than
3 million patients chronically infected with HCV, making this
disease a major public health problem. HCVI leads to chronic
liver disease states such as cirrhosis and the need for transplan-
tation. There is little published data on the cost of HCVI in
Brazil. The aim of this study is to investigate medical resource
use and direct treatment costs for each state of HCV infection
from the perspective of the private medicine payers in Brazil.
METHODS: Three Delphi panels were performed, one with
hepatologists, one with intensivists and another with oncologists
in order to delineate practice patterns and to obtain resource uti-
lization for routine treatment and monitoring, adverse event
management and other clinical parameters representative 
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of community physicians management of HCV infection.
Responses were obtained from six hepatologists, six intensivists
and six oncologists from various centers in Brazil with experi-
ence of treating HCVI. RESULTS: The expected annual costs per
each disease stage, not treated with antiviral medication, per
patient were: R$1.069 for mild chronic hepatitis, R$1,277.00
for moderate chronic hepatitis, R$1,522.00 for compensated 
cirrhosis, R$15,932.00 for ascites, R$31,352.00 for refractory
ascites, R$21,427.00 for variceal hemorrhage, R$106,922.00 for
hepatic encephalopathy, R$20,884.00 for hepatocellular carci-
noma, R$136,900.00 for liver transplantation, R$10,540.00
liver transplantation after the ﬁrst year and R$789.00 for remis-
sion. CONCLUSIONS: These cost data can be used to model
disease burden in Brazil. The costs increase dramatically in the
more advanced disease health states. Probably, slowing the pro-
gression to these disease states may be cost saving. One USD =
2.57 Brazilian Reais at the moment of the study.
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OBJECTIVES: GERD is one of the most common gastrointesti-
nal disorders. Knowledge on epidemiologic data, treatment
guidelines and patterns and economic details is limited.
METHODS: Extensive desktop research was conducted for
North America, Western and Eastern Europe and Australia using
MEDLINE, EMBASE and Cochrane databases (1995–2004),
telephone interviews, Internet searches (2000–2004). For struc-
tured search all MESH terms applying to GERD, epidemiologic
data, treatment patterns, costs and related issues (22 in total)
were used. RESULTS: Extensive review of obtained literature
revealed 162 articles and other sources of information (websites,
telephone contacts) for further evaluation. Prevalence of weekly
GERD symptoms ranges from 4% (Canada) to 20% (USA). 
Population-based prevalence data are lacking for Austria,
Germany and Eastern European countries. General recommen-
dations for management of GERD consist of symptom-oriented
measures with lifestyle changes and administration of antacids,
Proton-Pump-Inhibitors (PPI) or H2-Receptor-Antagonists. Spe-
ciﬁc guidelines with recommendations on drug treatment exist
in all countries except most of Eastern Europe. Treatment pat-
terns widely follow guidelines with variations in drug dosage and
administration period. Peer-reviewed literature revealed 20 
cost-of-illness studies (16 USA, 1 Canada, 3 Western Europe, 0
Eastern Europe and Australia). In North America total direct
cost (TDC) ranged from €360–€800/a (Canada €700/a). Western
European cost-of-illness studies exist only for Sweden (TDC
€930/a) and Italy (TDC €300/a). From third party payers’ 
perspective main cost drivers are medication (about 40%) and
outpatient care (about 60%). CONCLUSIONS: Although preva-
lence of GERD is high, only few studies focus on its economic
burden, most of them conducted in the USA. Treatment guide-
lines show comparatively uniform features in all investigated
countries, especially concerning the recommendation of PPI
usage. Treatment patterns show wide usage of PPI, except in
Eastern Europe where treatment patterns assumably resemble
those in Western Europe, probably with limitations due to the
countries’ health care systems’ possibilities.
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Artiﬁcial liver support systems (ALS) are a new therapeutic
approach for patients with acute liver failure (ALF) or acute-on-
chronic liver failure (ACLF). Using this technology patients
should have a better chance for regaining their own liver func-
tion or for successful bridging to transplantation. Treatment
costs in Germany are €10–15,000 per patient. OBJECTIVES: To
determine and summarize the scientiﬁc evidence on medical efﬁ-
cacy and economic effectiveness of the use of ALS in patients
with ALF or ACLF. METHODS: In an extensive systematic lit-
erature search in all relevant medical and economic data bases
all published studies on ALS were identiﬁed and systematically
described. All results concerning the treatment of ALF or ACLF
were extracted and if possible synthesized to ﬁnal recommenda-
tions. RESULTS: Three different artiﬁcial liver support systems
could be identiﬁed. For Biologic-DT® neither of the identiﬁed
studies reported medical or economic beneﬁts. For Prometheus®
no randomized controlled studies reporting medical or economic
effects are available. For MARS (Molecular adsorbing recircu-
lating system) for patients with ACLF a signiﬁcant improvement
of clinical parameter and 30d-survival could be demonstrated.
First health economic studies with short time horizon report
costs per QALY of €60,000 and conclude that prolonging the
time horizon would improve cost-effectiveness. All studies show
methodological limitations. CONCLUSION: The present scien-
tiﬁc evidence according to published trials on ALS does not show
any medical or economic beneﬁt of the liver support systems 
BioLogic-DT® and Prometheus®. The limited evidence for the
beneﬁt of the system MARS gives hints that ACLF patients might
clinically beneﬁt and that cost-effectiveness is acceptable. Future
randomized controlled studies with large sample size and health
economic models to estimate long term beneﬁts are necessary to
conﬁrm these results.
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OBJECTIVES: The evidence base for cost-effectiveness analyses
(CEA) often consists of a series of randomised controlled trials
making pair-wise comparisons between several alternative treat-
ments (A vs. B, A vs. C, B vs. D, etc). Furthermore, each trial
may report results at one or more, different, follow-up times. In
order to obtain unbiased estimates of treatment efﬁcacy, and to
produce an appropriate uncertainty analysis in the context of a
CEA, any synthesis of the evidence must ensure that the uncer-
tainty structure arising from the pattern of randomisation is cor-
rectly captured and propagated. METHODS: We studied a set
of 41 randomised trials looking at the healing rates of six treat-
ments for gastro-oesophageal reﬂux disease (GORD). Each trial
reported the healing rate at one or more (average 1.8) follow-up
times at 4, 6, 8, or 12 weeks. There are a possible 15 pair-wise
comparisons between 6 treatments, but, overall, the dataset pro-
vides direct information on only 9 of these, 5 at 4 weeks, 4 at
6, 8 at 8 and 6 at 12. We developed a series of hierarchical
models that “borrow strength” across the incomplete network
of treatment comparisons and also across time points. RESULTS:
We propose an approach that distinguishes between the model
